Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Jan Lycke

Professor, adjungerad

Jan Lycke
Professor, adjungerad
jan.lycke@gu.se
+46 31-342 9047
0733-109149

Postal Address: Gröna stråket 11, plan 3, 41345 Göteborg
Visiting Address: Neurosjukvården, Gröna stråket 11, plan 3, SU/Sahlgrenska sjukhuset , 41345 Göteborg


Department of Clinical Neuroscience at Institute of Neuroscience and Physiology (More Information)
Box 430
405 30 Göteborg
Visiting Address: Blå stråket 7, plan 3, Sahlgrenska , 413 45 Göteborg

Latest publications

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell et al.
European Journal of Neurology, Journal article 2019
Journal article

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni et al.
Acta Neurologica Scandinavica, Journal article 2019
Journal article

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl, Ingrid Kockum, Mohsen Khademi, Kaj Blennow, Jan Lycke et al.
Multiple Sclerosis Journal, Journal article 2018
Journal article

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos, Amit Bar-Or, Bruce A.C. Cree, Robert J. Fox, Gavin Giovannoni et al.
The Lancet, Journal article 2018
Journal article

Showing 1 - 10 of 67

2019

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell et al.
European Journal of Neurology, Journal article 2019
Journal article

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni et al.
Acta Neurologica Scandinavica, Journal article 2019
Journal article

2018

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl, Ingrid Kockum, Mohsen Khademi, Kaj Blennow, Jan Lycke et al.
Multiple Sclerosis Journal, Journal article 2018
Journal article

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos, Amit Bar-Or, Bruce A.C. Cree, Robert J. Fox, Gavin Giovannoni et al.
The Lancet, Journal article 2018
Journal article

Showing 1 - 10 of 67

Page Manager: Katinka Almrén|Last update: 9/1/2015
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://neurophys.gu.se/english/departments/clinical_neuroscience_and_rehabilitation/about-us/staff/?feedbackForm=true&returnAddress=http%3A%2F%2Fneurophys.gu.se%2Fenglish%2Fdepartments%2Fclinical_neuroscience_and_rehabilitation%2Fabout-us%2Fstaff%2F%3FfeedbackForm%3Dtrue%26returnAddress%3Dhttp%253A%252F%252Fneurophys.gu.se%252Fenglish%252Fdepartments%252Fclinical_neuroscience_and_rehabilitation%252Fabout-us%252Fstaff%252F%253Fprint%253Dtrue%2526languageId%253D100001%2526userId%253Dxlycja%26recipientName%3DKatinka%2BAlmr%25E9n%26encodedEmail%3Da2F0aW5rYS5hbG1yZW5AbmV1cm8uZ3Uuc2U%26print%3Dtrue%26languageId%3D100001%26userId%3Dxlycja&recipientName=Katinka+Almr%E9n&encodedEmail=a2F0aW5rYS5hbG1yZW5AbmV1cm8uZ3Uuc2U&languageId=100001&userId=xlycja
Utskriftsdatum: 2019-10-14